7266 related articles for article (PubMed ID: 15893279)
21. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A
Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579
[TBL] [Abstract][Full Text] [Related]
22. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
23. Maintenance of remission in Crohn's disease.
Gonvers JJ; Juillerat P; Mottet C; Felley C; Burnand B; Vader JP; Michetti P; Froehlich F
Digestion; 2005; 71(1):41-8. PubMed ID: 15711049
[TBL] [Abstract][Full Text] [Related]
24. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
[TBL] [Abstract][Full Text] [Related]
25. [Cyclosporine in inflammatory bowel disease].
Colomina Avilés J; Pascual Pérez R; Ortuño Cortés J; García García A; Del Pino Cuadrado J
An Med Interna; 1998 Apr; 15(4):214-8. PubMed ID: 9608068
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
27. [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease].
Kull E; Beau P
Gastroenterol Clin Biol; 2002 Apr; 26(4):367-71. PubMed ID: 12070412
[TBL] [Abstract][Full Text] [Related]
28. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
Sandborn WJ
Am J Gastroenterol; 1997 May; 92(5):876-9. PubMed ID: 9149205
[TBL] [Abstract][Full Text] [Related]
29. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
30. Review article: Medical therapy for fistulizing Crohn's disease.
Bressler B; Sands BE
Aliment Pharmacol Ther; 2006 Nov; 24(9):1283-93. PubMed ID: 17059510
[TBL] [Abstract][Full Text] [Related]
31. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
32. Current status of drug therapy for inflammatory bowel disease.
Peppercorn MA
Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
[TBL] [Abstract][Full Text] [Related]
33. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
34. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes.
Reddy D; Murphy SJ; Kane SV; Present DH; Kornbluth AA
Am J Gastroenterol; 2008 May; 103(5):1203-9. PubMed ID: 18422816
[TBL] [Abstract][Full Text] [Related]
35. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
36. Thiopurine therapy in inflammatory bowel disease.
Ha C; Dassopoulos T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
[TBL] [Abstract][Full Text] [Related]
37. Medical treatment of inflammatory bowel diseases.
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2005 Jul; 21(4):443-7. PubMed ID: 15930985
[TBL] [Abstract][Full Text] [Related]
38. [Immunosuppressive therapy of inflammatory diseases of the large intestine].
Rumiantsev VG; Rogozina VA; Osina VA
Eksp Klin Gastroenterol; 2004; (6):89-98, 165. PubMed ID: 16259448
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy of inflammatory bowel diseases].
Wichan P; Chojnacki J; Wojtuń S
Pol Merkur Lekarski; 2004; 17 Suppl 1():40-3. PubMed ID: 15603345
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
